First-in-class humanized FSH blocking antibody targets bone and fat
Sakshi Gera, Damini Sant, Shozeb Haider, Funda Korkmaz, Tan‐Chun Kuo, Mehr Mathew, Helena Pérez‐Peña, Honglin Xie, Hao Chen, Rogerio Batista, Kejun Ma, Zhen Cheng, Elina Hadelia, Cemre Robinson, Anne Macdonald, Sari Miyashita, Anthony A. Williams, Gregory Jebian, Hirotaka Miyashita, Anisa Gumerova, Kseniia Ievleva, Pinar J. Smith, Jiahuan He, Vitaly Ryu, Victoria DeMambro, Matthew Quinn, Marcia Meseck, Se‐Min Kim, T. Rajendra Kumar, Jameel Iqbal, Maria I. New, Daria Lizneva, Clifford J. Rosen, Aaron J.W. Hsueh, Tony Yuen, Mone Zaidi
Abstract
Significance We report the development and characterization of a first-in-class humanized antibody to follicle-stimulating hormone (FSH). We have shown previously that blocking FSH action on its receptor increases bone mass, reduces body fat, and enhances energy expenditure. Furthermore, FSH has been reported to increase serum cholesterol. Therefore, an anti-FSH agent has the potential of preventing and treating obesity, osteoporosis, and hypercholesterolemia, diseases that affect millions of women and men worldwide. Our study provides the framework for further preclinical and subsequent clinical testing of our humanized antibody to FSH.